Following infection, many secreted poxvirus proteins are able to modulate the host immune response through interactions with cytokines or components of the complement pathway. A comparison of the secreted protein profiles from cells infected with vaccinia Western Reserve (W-WR), cowpox virus Brighton strain, or rabbitpox virus (RPV) showed an abundant 35-kDa protein present only in the supernatants from RPV-infected cells. The gene encoding this protein was identified and mapped by N-terminal sequencing of the protein. Examination of the predicted amino acid sequence showed it to be identical to the 35-kDa secreted protein of the Lister strain of vaccinia virus described bY Patel et aL (1990 , J. Gen. ViroL 71, 2013-2021. The counterpart of this gene in the commonly studied W-WR strain is truncated and encodes a 7.5-kDa protein under control of the well-characterized p7.5 promoter. While nonessential for replication in cell culture, conservation of this gene in at least two orthopoxvirus strains suggested that this protein might play an important role in vivo. Following intranasal inoculation of Balb/c mice at several doses (103, 104, or 10 S PFU), a mutant of RPV lacking a functional 35-kDa gene (RPVA35) appeared to induce an earlier onset and more severe illness at low, sublethal doses (103 PFU) than was observed with wild-type (wt) RPV. At higher doses (104 or 10 s PFU), the behavior of wt RPV and RPVA35 became indistinguishable and the overall LDso values were similar. Intradermal infection of rabbits simultaneously, at separate sites, with RPV and RPVA35 showed no gross or microscopic differences between either primary skin lesions or viremic extension of each virus into the lungs. Therefore, this abundant secreted protein does not appear to play a major role in the virulence of the virus.
INTRODUCTION
In recent years, a number of poxvirus-encoded proteins have been shown to interact with components of the host inflammatory and immune systems. Deletion of such genes frequently results in virus attenuation (see Turner and Moyer, 1990; Buller and Palumbo, 1991 , for reviews). The vaccinia virus (W)-encoded complement control protein (VCP, the O21L ORF) acts to inhibit the complement cascade (Kotwal and Moss, 1988; Kotwal et al., 1990; Isaacs et aL, 1992a) . W (the B15R ORF) and cowpox virus (CPV) produce a protein which binds to interleukin-1/3 (Alcami and Smith, 1992; Spriggs et aL, 1992) . Myxoma virus produces proteins which bind to TNF (Upton et al., 1991) and interferon-?, as well as a serpin (SERP-1)which inhibits several plasma proteases (Lomas et al., 1993; Macen et al., 1993) . A serpin encoded by CPV (SPI-2 or crmA) acts to inhibit the activation of interleukin-1/3 (Ray et al., 1992) . Other poxvirus proteins, such as the M11L ORF of myxoma virus Opgenorth et al., 1992) and B5R ORF (ps/hr) of vaccinia and rabbitpox viruses (Takahashi Nishimaki et al., 1991; Engelstad et al., 1992;  ~To whom correspondence and reprint requests should be addressed. Engelstad and Smith, 1993; Isaacs eta/., 1992b; Wolffe et al., 1993; Martinez-Pomares et al., 1993) , have profound effects on viral virulence but specific functions in vivo have not yet been ascribed to these proteins.
Most of these proteins are secreted and found in the supernatants from infected cells. Indeed, only the crmA (Ray et al., 1992) and M11L ORF of myxoma are believed to be intracellular or restricted to • the surface of the cell. The fact that many viral secreted proteins influence virulence suggests that any major secreted viral protein is an excellent candidate for a viral gene which might modify the host response to infection. Two major secreted proteins are produced by wild-type rabbitpox virus (RPV)-infected cells. One of these has been previously identified as the RPV (ORF C3L) homolog of the VCP protein encoded by the Western Reserve strain of vaccinia virus (W-WR) (ORF C21 L) (Bloom et al., 1991 (Bloom et al., , 1993 . However, a second, 35-kDa protein, the most abundant protein secreted by this virus, is unique to RPV and is not secreted by either W-WR or CPV. We report here the identification of that protein and show it is similar if not identical to a 35-kDa protein secreted by WLister (Patel et al., 1990 ) and related to a much smaller protein (7.5 kDa) in W-WR controlled by the intensively studied P7.5 promoter, and that like the W-soluble IL-1/~ receptor homolog (Spriggs et al., 1992 ; AIcami and , the production of this 35-kDa protein by RPV may, at low doses, act to retard the onset of illness and loss of weight in infected animals.
MATERIALS AND METHODS

Viruses and cells
The wild-type (wt) Utrecht strain of rabbitpox virus and vaccinia virus strain WR were obtained from the American Type Culture Collection. The wild-type Brighton red strain of cowpox virus was obtained from Dr. David Pickup of Duke University. The white pock deletion mutant of RPV, RP#hr23, was originally obtained from Frank Fenner and has been described in detail (Bloom et aL, 1991; Edwards etaL, 1988; Moyer eta/., 1980; . CV-1 and RK-13 cells were maintained in GIBCO minimal essential medium (MEM) supplemented with 5% fetal bovine serum, 2 mM glutamine, 50 units/ ml penicillin, 50 #g/ml streptomycin, 1 mM sodium pyruvate, and 0.1 mM MEM nonessential amino acids (GIBCO).
Preparation of supernatants from infected cells
Monolayers of CV-1 cells in 150-mm dishes were infected at a moi of 5 in OptiMEM medium supplemented with 2 mM glutamine, 50 units/ml penicillin, 50 ffg/ml streptomycin, 1 mM sodium pyruvate, and 0.1 mM MEM nonessential amino acids (GIBCO) (Opti-MEM + supplements). One hour after infection the inoculum was removed, the cells were extensively washed with phosphate-buffered saline, pH 7.2 (PBS), and 20 ml of Opti-MEM + supplements was added. The supernatants were collected 24 hr later and clarified at 10,000 g at 4°0 for 60 min.
Preparation of 35S-labeled secreted protein extracts
Monolayers of CV-1 or RK-13 ceils were infected at a moi of 10 in MEM supplemented with 1% fetal bovine serum, 2 mM glutamine, 50 units/ml penicillin, 50 ffg/ml streptomycin, 1 mM sodium pyruvate, and 0.1 mM MEM nonessential amino acids (GIBCO). Radiolabeling of viral proteins was achieved by replacing the media with MEM containing 50 ffCi/ml of [35S]Translabel (ICN Biomedicals, inc.) and one-tenth the usual content of methionine and cysteine. The supernatants were collected at the end of the labeling period.
Protein microsequencing
Protein microsequencing was done in collaboration with the protein core facility of the Interdisciplinary Center for Biotechnology Research (ICBR) of the University of Florida. Supernatants from Mock-and wt RPV-infected CV-1 cells were prepared as described previously, concentrated X 100 using a Centriprep-10 concentrator (Amicon), and electrophoresed in a sodium dodecyl sulfatepolyacrylamide gel (SDS-PAGE) consisting of a 4% acrytamide stacking gel and a 10% separating gel. Following electrophoretic separation, proteins in the unstained gel were transferred overnight at 4°0 to a Problot membrane at 20V in a buffer containing 10 mM MES, pH 6, and 20% methanol. Proteins were visualized on the membrane by staining with 0.02% Coomassie blue in 40% methanol and 5% acetic acid. The membrane was then washed with distilled water and air-dried. The band corresponding to the RPV 35-kDa secreted protein was cut from the membrane and microsequenced using an Applied Biosystems gas-phase sequencer.
Construction of a mutant disrupted in the gene encoding the 35-kDa protein (RPVA35)
The plasmid pD357 (Patel etaL, 1990 ) contains a fragment of W-Lister DNA where the 35-kDa protein is deleted and replaced by the /~-galactosidase gene under control of the 35-kDa protein promoter (p7.5 in W-WR) flanked by viral sequences upstream (~1500 bp) and downstream (~250 bp) of the replaced W-Lister 35-kDa gene. The plasmid was used for the construction of the recombinant RPV carrying the fl-galactosidase gene as a complete replacement for the 35-kDa gene and was kindly provided by Dr. Nigel D. Stow. Monolayers of CV-1 cells in 60-mm dishes were transfected with 10 fig of plasmid pD357 as described previously (Turner and Moyer, 1992) . The selection of RPV mutants lacking the 35-kDa protein (RPVZ&35) was done by plaque purification in the presence of 150 #g/ml of 5-bromo-4-chloro-3-indolyl-/3-u-galactopyranoside (X-gal) until no further segregation of "white" plaques was observed. The putative recombinant virus was amplified in RK-13 cells and further analyzed as described in the text.
Animals and infections
Female Balb/c mice (Harlen, Sprague-Dawley, Inc., Indianapolis, IN) were 6 to 8 weeks old, virus free, and weighed between 16 and 20 g. Intranasal virus infection, blood and organ collection, and virus titrations were performed as previously described (Thompson et al., 1993) . Infectious doses ranged from 102 to 106 plaque forming units (PFU) and the LDso was determined by the method of Reed and Meunch (Reed and Meunch, 1938) . Virus titers were verified before and following each experiment involving animals to ensure the accuracy of the doses administered.
Adult female, New Zealand White rabbits (M & P Rabbits, Bronson, FL) were inoculated intradermally in four sites with 0.1 ml PBS containing 500 PFU of wt RPV along the left side of the back and in four sites with 500 PFU of RPVA35 along the right side of the back; a single intradermal injection of 0.1 ml PBS was used as a negative control. The rabbits were observed twice daily for the development of cutaneous lesions and systemic signs of illness. A 6-mm diameter Baker's biopsy punch (Baker Cummins Pharmaceuticals, Inc., Miami, FL) was used to obtain skin specimens at 3, 5, and 7 days after inoculation from individual injection sites for microscopic examination. Rabbits that became moribund during the infection were euthanatized by intravenous injection of sodium pentobarbital.
Quantitation of interleukin-6 and tumor necrosis factor
Four groups of six mice were infected intranasally with 10 4 or 10 6 PFU of either RPVZ&35 or RPV. An additional group of six mice served as negative controls and were inoculated intranasally with PBS only. At 3 and 5 days after infection, three mice within each group were bled to obtain serum for quantitation of interleukin-6 (IL-6) and tumor necrosis factor (TNF). The mice were sacrificed by cervical dislocation immediately after collecting a blood specimen. The trachea was then exposed, through a ventral cervical incision, and cannulized with a nasal-lacrimal needle through a small incision made between two adjacent tracheal rings. The nasal-lacrimal needle was secured within the tracheal lumen by a simple interrupted suture which surrounded the trachea. One milliliter of PBS was then injected through the nasal-lacrimal needle and then aspirated back into a 3-ml syringe twice to lavage the trachea, bronchi, and lower airways. A monoclonal antibody capture ELISA was used to measure serum and intrapulmonary IL-6 (Pharmingen, San Diego, CA) and TNF (Pharmingen) concentrations; recombinant mouse TNF-~ (Genzyme Diagnostics, Cambridge, MA) and IL-6 (Pharmingen) were used to establish standard curves for the ELISA assays.
RESULTS
Characterization of the major secreted proteins from wt RPV-, CPV-, and W-WR-infected cells A comparison of the major proteins present in the media from mock-, RPV-, CPV-, and W-WR-infected cells showed that each of these poxviruses produced a different profile of secreted proteins (Figs. 1A and 1B) . Proteins of the same molecular weight as VCP (29 kDa), the major W-WR secreted protein and a homolog of the C4b binding protein of complement (Isaacs eta/., 1992a; McKenzie etaL, 1992; Kotwal eta/., 1990; Kotwal and Moss, 1988) were also found in the supernatants from RPV-and CPVinfected cells. In the case of RPV this 29-kDa protein (RPV ORF C3L) has been shown to be the RPV homolog of the vaccinia VCP since= (1) The 29-kDa protein was recognized by antibodies raised against VCP (data not shown); (2) the 29-kDa protein was absent in the supernatants from cells infected with RPV#hr23 which does not contain the gene coding for the VCP (Fig. 1B) ; and (3) the 29-kDa protein was present in the supernatants from the recombinant virus #23Eco3 (Bloom eta/., 1991) , which contains a copy of the C3L RPV gene (data not shown). One additional major protein was present in the supernatants from both RPV-and CPV-infected cells (Fig.  1A ). In the case of CPV, the unique protein was smaller and more that the putative VCP. In RPV-infected cell supernatants, the additional protein was also more abundant than VCP and larger, with an apparent molecular weight of 35 kDa. This 35-kDa protein was also secreted by RPV#hr23-infected cells and was easily detected in both RPV-and RPV#hr23-infected, concentrated cell supernates by Coomassie blue staining (Fig. 1B) .
Mapping the gene coding for the RPV 35-kDa secreted protein Identification of the gene encoding the RPV major secreted protein was achieved through direct sequencing of the N-terminus of the protein (see Materials and Methods), which yielded the sequence MPASLQQSS. Screening of databases revealed the identical sequence in a protein described previously (Patel eta/., 1990) as a 35-kDa major secreted protein of the Lister strain of W. In the Lister strain, the gene was mapped and shown to be present in two copies within both inverted terminal repeats (Patel eta/., 1990) . It was also shown that this protein was not required for W-Lister growth in tissue culture. Using primers, based on internal 5' and 3' se- quences of the W-Lister 35-kDa protein gene sequence, it was possible with PCR to amplify an RPV gene homolog from RPV DNA. This 800-bp PCR product hybridized to both the RPV Hindlll B-and C-terminal restriction fragments located at both extremes of the viral DNA, indicating the presence of two copies of the gene ( Fig. 2A) . In W-Lister, the expression of this gene is under the control of the strong early/late PT.~ promoter (Patel et al., 1990; Cochran et al., 1985) , which in W-Wfq controls expression of a truncated (7.5-kDa) version of this protein (Cooper et al., 1981b) . Based on (1) the successful amplification of an RPV sequence of appropriate size using PCR primers from the W-Lister sequence, (2) the size of the PCR product, (3) the relative molecular weight of the protein, (4) its secretion into the media, and (5) its synthesis at both early and late times postinfection (Fig. 4) , it becomes apparent that the RPV 35-kDa protein and that described for the W-Lister strain are very similar if not identical.
As final proof, a plasmid containing the /~-galactosidase gene flanked by portions of the W-Lister 35-kDa protein gene (external to the 800-bp probe discussed above) was used to transfect RPV-infected cells. The plasmid (provided by Dr. Nigel Stowe) was designed by them to replace the 35-kDa gene by the/~-galactosidase gene in W-Lister. RPV recombinants containing the ~-galactosidase gene were selected by repeated picking of individual RPV plaques which stained blue in the presence of Xgal and were stable to segregation (see Materials and Methods) . DNA analysis of several of these recombinants, showed they lacked both copies of the 35-kDa homolog of the W-Lister and instead contained two copies of the /3-galactosidase gene consistent with the expected replacement of a diploid 35-kDa gene with /:Fgalactosidase (Fig. 2B) . We refer to this mutant(s) as RPVA35. Finally, when secreted protein patterns from RPV and RPVA35 were compared, the major RPV 35-kDa protein secreted at both early and late times in RPVinfected ceils was completely absent in supernatants of cells infected with RPVz&35 (Fig. 4) . Based on these results, there is little doubt that the RPV 35-kDa secreted protein is the homolog of the W-Lister protein.
As shown in Figure 3 , the gene encoding the W-Lister strain 35-kDa protein is not only well conserved among several orthopoxviruses (variola; Massung et aL, 1993) , OPV (Pickup et aL, 1982) , and W-Copenhagen (Goebel et al., 1990) , but also in Shope fibroma virus (SFV), a leporipoxvirus (Upton et aL, 1987) . In all these cases, the predicted proteins are highly hydrophilic and acidic (p/ ranging from 4.29 to 4.64). The W-Lister, CPV, variola, and SFV proteins contain an N-terminal hydrophobic region which in the case of the Lister strain acts as a signal peptide (Patel et aL, 1992) . Our direct sequencing of the N-terminal portion of the 35-kDa RPV protein suggests that this hydrophobic region is also removed during the secretion of the RPV protein (Fig. 4) . We would predict that the variola protein is secreted as well, but that the W-Copenhagen homolog, which lacks the putative signal peptide, is not. A second W-WR protein related to the SFV T10RF was discovered earlier . This ORF, named SaIF-4L, encodes a 219-aminoacid protein with a predicted molecular weight of 25 kDa and also contains a potential signal sequence. However, this 25-kDa protein does not share significant homology with the family of 36-kDa protein genes described here, Indeed, as mentioned, the 35-kDa protein gene homolog in W-WR is truncated and yields only a 7.5-kDa protein (Patel et aL, 1990) . It is curious to note that CPV does not secrete a 35-kDa protein as might be expected from the primary amino acid sequence (246 amino acids) (Pickup et aL, 1982) which is very similar to that of WLister (258 amino acids) (Patel etaL, 1990) shown in Fig.  3 . CPV does, however, produce a unique, very abundant smaller secreted protein (Fig. 1) . Whether this protein is related to the secreted 35-kDa protein of RPV has not been established. (Goebel eta/., 1990) , variola virus, ORF G5R (Massung eta/., 1993) , CPV, and the SFV, ORF T1 (Upton et al., 1987) . A consensus sequence was deduced from the W-Lister and W-Copenhagen strains, cowpox, and vadola sequences. This consensus sequence was then compared to the SFV sequence and identities and/or conservative changes between the SFV and orthopoxvirus consensus sequences are shown. The amino acid sequence obtained from the RPV 35-kDa protein by direct sequencing is underlined in the sequences.
orthopoxvirus strains highly passaged in cell culture (W-WR and W-Copenhagen) but otherwise perfectly viable, suggests that this protein is nonessential for growth in cell culture. Truncation of the protein to 7.5 kDa in W-WR and loss of the signal portion of the protein in W0openhagen could simply be a manifestation resulting from the fact that these intensively studied strains have also been among the most extensively passaged strains in cell culture. As was demonstrated for W-Lister, we have shown the 35-kDa protein of RPV is not required for growth in a variety of cell lines in culture. The cell lines examined include rabbit (RK-13), human (A549), chicken embryo fibroblasts, swine (PK-15), monkey (CV-1), and rodent (RAT-2) ceils. The RPVA35 mutant produced normal titer stocks and plaques that were indistinguishable from RPV. Finally, the RPVA35 mutant produced red, hemorrhagic pocks on the chorioallantoic membrane of embryonated eggs which were indistinguishable from those of RPV (data not shown). Nevertheless, as discussed earlier, the involvement of several secreted proteins in viral virulence and pathogenesis implied that this protein could also play an important role in the in viva pathogenesis of the virus. 1993). Following the procedures described previously (Thompson et al., 1993) , 40 mice, separated into groups of eight, were infected intranasally with RPVz&35 using 10-fold serial dilutions of virus which ranged from 102 to 106 PFU. Another group of mice was infected with RPV. Eight mice served as negative controls and were inoculated with PBS only. Mice were examined twice daily for clinical signs of illness. Body weight was recorded daily, and blood was sampled 4 and 6 days after infection to measure viremia.
Mice infected with 102 PFU of either RPVA35 or RPV showed no decrease in body weight nor clinical signs of illness following intranasal infection. Mice infected with 103 PFU of RPVA35 exhibited detectable (P < 0.05) weight loss and clinical signs of illness manifested by ruffled fur, decreased activity, increased huddling, and tachypnea. All mice eventually recovered. However, mice infected with 103 PFU of RPV remained healthy and showed neither clinical signs of illness nor weight loss (Fig. 5 ). Mice infected with 104 PFU of RPVA35 appeared to exhibit a somewhat more severe and rapid onset of illness, as well as a more substantial loss of weight compared to mice infected with 104 PFU of RPV (Fig. 5 ) but these differences were small. Ultimately, however, the clinical signs of illness became identical in the two groups of mice. All mice infected with 104 of either RPVA35 or RPV eventually recovered. However, four of eight mice infected with 106 PFU of RPVA35 and two of eight mice infected with RPV succumbed 7-9 days after infection. Infection with 106 PFU of either RPVA35 or RPV was uniformly lethal; however, once again, the disease manifestations were more rapid and more severe in mice infected with RPVA35, as six of eight mice succumbed by Day 6 after infection as compared to RPV where only one of eight mice had succumbed. The lOgic LD6o of RPVA35 and RPV was 5.0 and 5.3, respectively.
Viremia was evaluated 4 and 6 days after infection with 10 4 and 106 PFU of RPVA35 and RPV. Viremia was detected in the majority of mice and there was no significant difference noted with either virus (Table 1) . Viremia persisted />6 days after infection at both doses and, in general, larger intranasal infectious doses resulted in higher levels of virus within the circulating blood.
Surviving mice infected with 10 4 PFU of RPV or RPVA35 at Day 13 of the infection were sacrificed. The brain and lungs were collected and virus titers were determined. No virus was found within the brain and only 4 of 16 mice had virus within the lungs (Table 1) . In contrast, all mice infected with 10 6 PFU of either RPV or RPVA35 succumbed within 5-10 days following inoculation. The brain and lungs of these mice were collected within 24 hr of-death and assayed for virus. All mice exhibited virus extension to the brain and had high concentrations of virus within the pulmonary parenchyma (Table 1 ). There was no statistical difference between titers in the organs of mice infected with either RPVA35 or RPV.
Because our initial pathogenesis studies in mice demonstrated a conspicuous absence of inflammatory cells associated with intranasal RPV infection (Thompson et a/., 1993) and because many poxvirus proteins secreted from infected cells can inhibit cytokine activity, we wished to measure the effect of local secretion of the 35-kDa protein from RPV-infected cells on local and systemic cytokine activity. Since an ordered cascade relationship has been observed for TNF, IL-1, and IL-6, in that TNF induces IL-1 production which then leads to synthesis of IL-6 (Abbas eta/., 1991), we elected to measure intrtapulmonary and serum concentrations of TNF and IL-6 following intranasal infection with RPV and RPVA35.
Intrapulmonary and serum concentrations of IL-6 and TNF following intranasal infection with RPVA35 and RPV revealed no significant biological differences between these viruses (data not shown). Intrapulmonary concentrations of IL-6 were, however, in all cases, significantly (P < 0.5) higher following infection with 106 PFU of virus as compared to 10 4 PFU of virus. The mean concentrations _+SD were 160 ± 60 and 130 + 40 pg/ml in mice infected with 10 4 PFU of RPV and RPVA35, respectively, as compared to IL-6 concentrations of 1110 + 880 and 1750 _+ 220 pg/ml in mice infected with 106 PFU of RPV and RPVA35, respectively. Negative control mice inoculated with PBS exhibited intrapulmonary IL-6 concentrations of 160 +_ 60 pg/ml.
Viral pathobiology in rabbits
Two adult rabbits were inoculated intradermally with RPV in four sites (500 PFU/site) along the left side of the back and in four sites with an identical dose of RPVA35 along the right side of the back. A single intradermal injection of PBS was used as a negative control. Erythematous foci, 5-10 mm in diameter, were observed at each virus injection site 2 days after intradermal inoculation. By 3 days after injection, the cutaneous lesions exhibited erythema and induration, measured 10-20 mm in diameter, and contained a 3-to 5-mm-diameter, central white area. The PBS control injection sites revealed no cutaneous lesions. By 5 days after inoculation, the central white area of the lesions varied in color from yellow-tan surrounded by a distinct erythematous rim to dark, redblack; these central lesions measured 5-10 mm in diameter and were surrounded by erythema and induration which measured 20-30 mm in diameter. The lesions were considered painful as the rabbits showed excessive cutaneous muscle twitching when the lesions were touched. The lesions exhibited little change between 5 and 7 days after inoculation, except the central areas became uniformly dark, red-black in color. At no time was a detectable difference observed between intradermal sites inoculated with RPV and RPVA35.
Biopsies of the cutaneous lesions were obtained 3, 5, and 7 days after inoculation. Microscopic examination of these biopsies revealed no differences between lesions associated with RPV and RPVA35 inoculation. At 3 days after infection the microscopic changes consisted of a mild periadnexal and dermal infiltration of a population of mixed inflammatory cells comprised predominantly of heterophils. By 5 days inoculation the numbers of heterophils within the dermis had increased, a lichenoid band of heterophils had formed beneath the basal epithelial cells, and vacuolar degeneration of the basal epithelial cells was prominent; heterophils were also observed within the basal epithelial cell layer and a distinct subcorneal vesicle with minimal accumulations of heterophils was also noted. By 7 days after inoculation the skin exhibited severe dermal necrosis, hemorrhage, and edema formation. Well-developed subcorneal pustules were present and necrosis of the basal epithelial cells and adnexal structures was severe. Systemic illness and viremia developed in both rabbits following intradermal inoculation. Viremia was readily indicated bythe appearance Of lesions in the ears. Pyrexia was the first sign of systemic illness and was apparent 2 days after infection. Additional systemic signs included a Viremia and organ virus titer expressed as the logic mean PFU/ml blood _+ SD and logic mean PFU/g tissue of mice exhibiting detectable virus, respectively. The lOgic level of virus within the blood and organs was 1.6 PFU/ml and 2.5 PFU/g, respectively.
Number of mice with detectable virus per number tested.
a mucoid nasal discharge, difficulty in breathing, and lethargy which developed 2-3 days later. The severity of these signs progressed and the rabbits were euthanatized 7 days after infection due to acute dyspnea. Lung tissue of both rabbits was removed and analyzed for the presence of RPV and RPVA35 in order to determine any viremic selectivity. Both viruses were readily obtained from the lungs of both rabbits with RPV showing a slight (4=1 and D1) predominance.
DISCUSSION
RPV-infected cells secrete two major proteins that are readily detected by Coomassie staining or 35S-labeling (Fig. 1) of infected cell supernates. The smaller of the two proteins was characterized as the RPV homolog of VCP, the complement inhibitory protein described in W-WR (Kotwal etaL, 1990; McKenzie etaL, 1992) . The larger (35 kDa) of these two secreted proteins, the subject of this study, is present in RPV but missing in the media from ceils infected with either W-WR or CPV.
A determination of the N-terminal amino acid sequence of this RPV 35-kDa protein was determined which allowed subsequent identification of the protein and mapping of the gene. Computer analysis of the gene sequence suggested it was similar if not identical to a previously described, major secreted 35-kDa protein from W-Lister-infected cells (Patel et al., 1990) . The 35-kDa W-Lister protein is encoded by a gene located at both ends of the viral genome within the inverted terminal repetitions (ITRs) and results in the gene being diploid. The promoter (PT.~) that regulates the gene in W-Lister results in 35-kDa protein expression at both early and late times of infection and has been extensively characterized in W-WR. The P7.5 promoter, so named because in W-WR, the ORF encodes a protein of only 7.5 kDa (Wittek et al., 1980b; Wittek and Moss, 1980; Wittek et al., 1980a; Cooper et aL, 1981a) , is also located within both ITRs of the viral DNA. It is reasonable to assume that the W-Lister and RPV 35-kDa proteins are more "complete" forms of the W-WR 7.5-kDa protein (Figs. 1  and 4) . The lack of homology between the gene encoding the 35-kDa major secreted protein of wt RPV to any proteins of known function makes it difficult to assign a role for this protein during infection.
The 35-kDa protein has been conserved among some (W-Copenhagen, CPV-BR, W-Lister, and variola virus) but not all orthopoxviruses and Shope fibroma virus (SFV), a leporipoxvirus (Fig. 3) . Based on the analogy to the W-Lister sequence which contains a signal peptide (Fig. 3) , one would predict protein secretion in other viruses, for example, CPV. However, one puzzling feature is that no secreted protein of 35 kDa was found in CPVinfected cells even though the nucleotide sequence suggests that the CPV protein would be expected to be nearly the same size (Fig. 3) and contains a hydrophobic N-terminal region that could function as a signal peptide. CPV does, however, secrete a unique, smaller protein ( Fig. 1 ) absent in both RPV and W-WR infections. Whether this is related to the 35-kDa protein is not known. Alternatively, a "down" promoter mutation for the CPV 35 kDa gene might lead to significantly lower levels of protein production in CPV-infected cells. In W-Copenhagen, the protein lacks a signal peptide and in W-WR is truncated to a 7.5-kDa polypeptide due to a frame-shift mutation in the gene.
These differences in the 35-kDa gene between various poxviruses make it clear that at least in cell culture, the 35-kDa protein is "non-essential" for viral growth. Other poxvirus genes nonessential for growth in tissue culture have been described, most of which are located toward either end of the viral genome (Meyer et al., 1980; Meyer and Rothe, 1980; Panicali etaL, 1981; Perkus etaL, 1986; Moss etaL, 1981; Lake and Cooper, 1980) . Indeed, extensive terminal deletions of viral DNA still result in a virus capable of growing in some cells in culture (Konishi et al., 1992) . In many cases, though, these "nonessential" genes have been shown to influence viral pathogenesis in the animal. It is possible, therefore, that retention of this secreted protein in RPV and W-Lister might reflect a rather specific biological role of the protein in these viruses. Wild-type RPV has been a valuable system in which to evaluate the contribution of different genes in the virulence of the RPV (Thompson et aL, 1993; Bloom et aL, 1991) . Therefore, mice infected intranasally with either wt RPV or RPVA35 were examined. Few differences between RPV and RPVA35 at higher infectious doses were noted. However, at lower doses reproducible, more severe disease symptoms were noted in mice infected with RPVz&35 (Fig. 5) which correlated with more rapid weight loss, even at a dose of 103 PFU at which RPV did not produce any detectable disease (Thompson et al., 1993) . Differences due to slight variations in viral titers which might produce these results were minimized by titering viral stocks both before and after each experiment. Though these differences are reproducible, having been noted in at least two independent experiments, the enhanced virulence noted in the RPVA35 infections is still quite small, and attributing significance to such small differences should be done with caution. For example, there are passage differences between wt RPV and any mutant generated from that stock. There is also the possibility of spontaneous mutations arising in nonintended regions of the genome. Finally, the flanking regions of the pD357 plasmid used to disrupt the 35-kDa gene were derived from W-Lister, not RPV. While these flanking WLister sequences are undoubtedly related to those of RPV, any sequence differences could lead to unanticipated changes in virulence.
There are, however, examples where disruption of a gene leads to enhanced virulence. Once such example is the W-WR IL-1/~ binding protein gene mutant (Alcami and Smith, 1992) . In that case, it was suggested that elimination of viral IL-1/g binding activity could result in elevated IL-1 levels which in turn could lead to the enhanced viral growth and toxicity observed (Alcami and Smith, 1992) . However, no more virus was recovered from mice infected with RPVA35 as compared to RPV, which indicated that any enhanced severity of the disease was not due to more efficient virus replication (Table 1). One possibility is that the RPVz~35 mutant infection could lead to the increased synthesis of one or more cytokines to toxic levels which could result in manifestation of systemic disease. The limited results obtained measuring the levels of IL-6 and TNF in the lungs and sera of infected animals indicated that this does not seem to be the case.
RPV, unlike W-WR, is a very lethal rabbit pathogen (Bedson and Duckworth, 1963) . Therefore, we also compared RPV and RPVA35 pathogenesis in rabbits by studying the lesions produced after intradermal inoculation and viremic efficiency. No differences were detected between the lesions produced by either RPV or RPVA35 even after microscopic examination. Both viruses spread efficiently to the lungs and skin with RPV being slightly more efficient. Calculations of accurate LDsos in rabbits will be difficult due to a great variability among different animals unless the effect is profound. Therefore, the only observed biological effect of the 35-kDa protein may be to delay somewhat the onset of clinical symptoms of disease in mice (Fig. 5) . Nevertheless, it is clear that under the conditions evaluated, the 35-kDa protein is a major secreted protein which, unlike other poxvirus secreted proteins, for example, the soluble TNF receptor Upton et aL, 1991) , the complement C4b binding protein homolog (Kotwal et al., 1990) , and the complement-related viral protein encoded by the BSR 0RF of W (Engelstad et al., 1992; Isaacs et a/., 1992b) and RPV (Martinez-Pomares et al., 1993) , does not appear to contribute to enhanced viral virulence. Rather, the 35-kDa protein, like the interleukin 1/5' receptor (Spriggs et aL, 1992; Alcami and Smith, 1992) , appears to act to retard the onset of clinical symptoms. Any viral gene which delays the demise of an animal could result in enhanced propagation of the pathogen and hence be advantageous.
